Cytokinetics (CYTK) EVP Andrew Callos Exercises Options, Sells Shares

What Happened
Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, exercised stock options to acquire 10,000 shares at $23.26 per share (cost $232,600) and on the same date sold 10,000 shares in an open-market transaction at $70.24 per share (proceeds $702,400). The net difference between the sale proceeds and exercise cost is about $469,800 before taxes and fees. The filing also reports a separate derivative disposition of 10,000 shares at $0.00; the form does not specify the reason for that $0.00 disposition.

Key Details

• Transaction date: 2026-08-31
• Exercise (M): 10,000 shares at $23.26 — total $232,600 (acquired)
• Sale (S): 10,000 shares at $70.24 — total $702,400 (disposed)
• Derivative disposition (M): 10,000 shares at $0.00 — $0 (reported separately)
• Shares owned after the transactions: not disclosed in the provided filing details
• Footnote: Options vest over 4 years (1/4 after 1 year, then monthly over 36 months) — see F1
• Filing timeliness: Reported 2026-08-31 and filed 2026-08-31 (timely)

Context
This is a common “exercise and sell” pattern (often called a cashless exercise) where an insider exercises options and sells shares immediately — it locks in gains but is not necessarily a signal about long-term view. The “M” code indicates option exercise/conversion; the separate $0.00 disposition is shown on the form but the filing does not explain its purpose (filings sometimes show similar lines for tax withholding or share conversions). The purchase component (exercise) shows insider benefited from appreciation since grant; the immediate sale converts that paper gain to cash.